AEGIRBIO AB
Magnasense AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs. The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases. It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform. The company was formerly known as AegirBio … Read more
Market Cap & Net Worth: AEGIRBIO AB (52Q)
AEGIRBIO AB (F:52Q) has a market capitalization of $123.58K (€120.40K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #47785 globally and #8021 in its home market, demonstrating a 11275.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AEGIRBIO AB's stock price €0.05 by its total outstanding shares 2646082 (2.65 Million).
AEGIRBIO AB Market Cap History: 2020 to 2026
AEGIRBIO AB's market capitalization history from 2020 to 2026. Data shows change from $5.71 Million to $123.58K (-44.16% CAGR).
AEGIRBIO AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AEGIRBIO AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 52Q by Market Capitalization
Companies near AEGIRBIO AB in the global market cap rankings as of March 19, 2026.
Key companies related to AEGIRBIO AB by market ranking:
- Microsoft Corporation (NASDAQ:MSFT): Ranked #5 globally with a market cap of $2.91 Trillion USD.
- Palantir Technologies Inc. Class A Common Stock (NYSE:PLTR): Ranked #38 globally with a market cap of $324.25 Billion USD.
- Palantir Technologies Inc. (NASDAQ:PLTR): Ranked #41 globally with a market cap of $321.50 Billion USD.
- Oracle Corporation (NYSE:ORCL): Ranked #52 globally with a market cap of $260.91 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5 | Microsoft Corporation | NASDAQ:MSFT | $2.91 Trillion | $391.79 |
| #38 | Palantir Technologies Inc. Class A Common Stock | NYSE:PLTR | $324.25 Billion | $178.15 |
| #41 | Palantir Technologies Inc. | NASDAQ:PLTR | $321.50 Billion | $152.77 |
| #52 | Oracle Corporation | NYSE:ORCL | $260.91 Billion | $152.90 |
AEGIRBIO AB Historical Marketcap From 2020 to 2026
Between 2020 and today, AEGIRBIO AB's market cap moved from $5.71 Million to $ 123.58K, with a yearly change of -44.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €123.58K | -91.48% |
| 2025 | €1.45 Million | +6832.47% |
| 2024 | €20.91K | -91.80% |
| 2023 | €255.04K | -48.12% |
| 2022 | €491.62K | -96.73% |
| 2021 | €15.05 Million | +163.56% |
| 2020 | €5.71 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of AEGIRBIO AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $123.58K USD |
| MoneyControl | $123.58K USD |
| MarketWatch | $123.58K USD |
| marketcap.company | $123.58K USD |
| Reuters | $123.58K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.